Kenvue (NYSE:KVUE) Announces Earnings Results

Kenvue (NYSE:KVUE) posted its quarterly earnings results on Thursday. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26, Zacks reports. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Price Performance

Kenvue stock traded down $0.96 during mid-day trading on Thursday, reaching $19.78. 25,806,181 shares of the company were exchanged, compared to its average volume of 12,577,004. The company has a fifty day simple moving average of $21.70 and a 200-day simple moving average of $21.95. The firm has a market cap of $37.93 billion, a PE ratio of 35.97, a PEG ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.15%. Kenvue’s payout ratio is presently 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group lowered their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.